Neurogene (NGNE) - Company Total Revenue
The operating revenue dynamics for Neurogene Inc. (NGNE) on the GURU.Markets chart demonstrate the current level of 0.00. This metric remains independent of market cycles, as the development of gene therapy is tied to FDA milestones. International tensions complicate the logistics of biomaterials and the execution of tests. The stability of the Rett syndrome patient base ensures the resilience of the Neurogene Inc. R&D ecosystem.
Comprehensive metric breakdowns and analytics for Neurogene Therapeutics (NGNE)
- current quotes and average value forecast:
- market capitalization indicators:
- book value of equity indicators:
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio Neurogene Inc.|NGNE - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Neurogene Therapeutics|NGNE - Company Debts|Debt to Book Value Ratio Neurogene Inc|NGNE - Company Long-Term Debts|Company Current Liabilities Neurogene|Interim Coverage Ratio neurogene.com
- financial results and valuation multiples details:
NGNE - Company Net Income|Net Profit Forecast Neurogene Inc.|NGNE - P/E Multiple|Forward Price to Earnings Multiple Neurogene Inc|NGNE - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Neurogene Inc|NGNE - Operating profit EBITDA|Net earnings per one share for the last twelve months Neurogene|NGNE - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months neurogene.com|NGNE - Earnings growth in current year|Expected net earnings per share growth next year Neurogene Inc.
- company sales and revenue statistics:
Comprehensive company analysis:Neurogene Inc. NGNE
Assessing the investment reliability of equity assets begins with an analysis of cash flow stability. This indicator captures daily product sales revenue, measuring the speed of technology commercialization within the fundamental value. For Neurogene Inc. (NGNE), this metric reflects the market success of gene therapies for rare pathologies, including results for the NGN-401 drug. This price action confirms the effectiveness of the gene delivery platform. By examining the company's sales chronology, an investor can objectively assess the business growth rate.
Key competitors
Company Sales Volume BIIB (Biogen)|Company Revenue Neurocrine Biosciences, Inc. (NBIX)|Company Revenue RGC (Regencell Bioscience Ltd)|Axsome Therapeutics, Inc. - Company Sales|ACAD (ACADIA Pharmaceuticals Inc) - Company Annual Revenue|Xenon Corp - Revenue and Sales Volume|Company Sales Revenue VKTX (Viking Therapeutics)|Supernus Pharmaceuticals (SUPN) - Company Revenue|Company Annual Revenue CPRX (Catalyst Pharmaceuticals, Inc.)|Company Revenue Denali Therapeutics Inc|Company Total Revenue Harmony Corp HRMY|Revenue and Sales Volume BHVN|Company Sales Amylyx Pharmaceuticals AMLX|Revenue and Sales Volume TRVI (Trevi Corp)|Company Gross Revenue Praxis Precision Medicines, Inc. (PRAX)|Anavex Life Sciences Corp - Revenue and Sales Volume|CeriBell Corp (CBLL) - Company Sales|Prothena Corp (PRTA) - Company Revenue|Company Total Revenue Alector Inc. (ALEC)|Company Sales ANNX|omeros.com (OMER) - Company Gross Revenue|Company Revenue AC Immune Corp (ACIU)|Company Total Sales VYGR|Revenue and Sales Volume NMRA (neumoratx.com)|SCLX - Company Sales|tevogen.com - Revenue and Sales Volume|Company Total Sales Volume Alpha Cognition Inc. (ACOG)|CGTX: Revenue and Sales Volume|IKT - Company Gross Revenue|Company Sales SAVA|Company Sales Assertio (ASRT)|Company Sales COYA (Coya)|Company Revenue VTGN (VistaGen Therapeutics Inc)|Company Revenue Ovid Therapeutics OVID|Revenue and Sales Volume Acumen Pharma ABOS|CervoMed, Inc. - Revenue and Sales Volume|Company Sales Revenue ATHE (alteritytherapeutics.com)|CLNN (Clene Nanomedicine) - Company Sales|Company Total Revenue PepGen Corp (PEPG)|Company Revenue Jupiter Neurosciences Inc|Company Total Revenue Relmada Therapeutics RLMD|Company Revenue Annovis Bio (ANVS)|GRCE - Company Total Revenue|Revenue and Sales Volume AIFF (Firefly Neuroscience, Inc)|Klotho Neurosciences Inc (KLTO) - Company Total Revenue|NeuroSense Therapeutics, Ltd. - Revenue and Sales Volume|RVPH - Revenue and Sales Volume|MetaVia Inc (MTVA) - Company Revenue|NRXS - Company Gross Revenue|Company Revenue heliusmedical.com|PASG - Company Total Sales Volume|Company Revenue Neuphoria (NEUP)|Company Gross Revenue Minerva|Revenue and Sales Volume ATHA (Athira Pharma Corp)|Company Sales Revenue ADXN|Alzamend - Revenue and Sales Volume|Cyclerion Therapeutics, Inc. (CYCN) - Company Sales|protagenic.com (PTIX) - Company Revenue|KTTA: Company Total Sales|CRGT (cortigent.com) - Revenue and Sales Volume|ATXI (Avenue Therapeutics) - Company Total Sales|Revenue and Sales Volume BCLI|Company Total Sales CARA|Company Revenue chromocell.com CHRO|Revenue and Sales Volume Eliem Therapeutics ELYM|ITCI: Company Sales|LBPH: Company Revenue|MRNS (Marinus Pharmaceuticals, Inc.) - Company Sales|NKGen - Company Sales Revenue|Company Revenue NeuroBo Pharmaceuticals, Inc.|Revenue and Sales Volume Sage Therapeutics Inc|Revenue and Sales Volume SNPX|TRVN - Company Total Revenue|Company Revenue vigilneuro.com VIGL|Company Gross Revenue Anew Medical (WENA)|cerevel.com - Revenue and Sales Volume
